There is a spectrum of issues in the development and distribution of antiretrovirals (ARVs) for paediatric patients. From a procurement standpoint, there are a range of challenges in securing the future of the paediatric ARV market. The development of optimized antiretroviral regimens for HIV-infected children remains one of the key pillars of the WHO’s new Treatment 2.0 initiative.

This session aims to discuss the market dynamics of supply and procurement for paediatric ARV formulations, particularly in resource-limited settings. Furthermore, it explores the issues related to the current and future pipeline of paediatric formulations, such as fixed-dose combinations (FDCs). The session further provides insight into the feasibility of developing new formulations that are pharmacologically relevant and easily administered/accepted to children. Perspectives from both originator and generic ARV manufacturers also are offered.